Polfurmetinib clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses polfurmetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Claturafenib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test polfurmetinib.
Studies
Open first, then newest update. How each study uses polfurmetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy AdultsCompletedPhase 1PfizerNCT07578636Written as Oral [14C] PF-07799544
- A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsActive, not recruitingPhase 1PfizerNCT05538130Written as PF-07799544
- Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544CompletedPhase 1PfizerNCT07563894Written as PF-07799933 tablets with PF-07799544 fasted
Codes
What other systems call polfurmetinib · ClinicalTrials.gg INT016700
- UNII (FDA) GST8GSH94BPOLFURMETINIBOne source FDA
- NCI Thesaurus C192683PolfurmetinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GST8GSH94B | POLFURMETINIB | One source FDA |
| NCI Thesaurus | C192683 | Polfurmetinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.